Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 17, 2013

View Archived Issues

Investigation of EPAC as a therapeutic target expands

A novel fusion protein inhibits IgE-mediated peanut allergy anaphylaxis in vitro and in vivo

French researchers design novel immunocytokines

ATR kinase inhibitors patented by Vertex Pharmaceuticals

Metabolys divulges novel glucose-lowering agents

Novel tyrosine-protein kinase SYK inhibitors reported in Takeda patent

Novartis patent reveals p53/Mdm2 interaction inhibitors

Incyte reports development of novel JAK inhibitors

TRPM7 inhibitors reported in NoNO patent

NIH launches program to find biomarkers for Parkinson's disease

Paladin Labs enters into agreement for novel neuroblastoma drug

QRxPharma and FDA confirm steps for resubmission of MoxDuo NDA

FDA will not meet action date for Ravicti NDA

FDA grants priority review for afatinib in NSCLC with an EGFR mutation

DTRA award supports PsiOxus' development of biodefense vaccine adjuvants

Health Canada approves Afinitor for advanced breast cancer

Novel inhibitor of JMJD2 histone demethylases reduces viral reactivation in vivo

siRNAs against serotonin 5-HT1A receptors produce antidepressant-like effects

Enrollment open in phase II study of Bendavia

Promising topline results from proof-of-concept burns trial of human skin substitute

FDA approves Protein Sciences' Flublok seasonal influenza vaccine

AT-13148 begins U.K. phase I study for cancer

Somatuline launched in Japan

Topline results from phase III heart failure study of Aranesp reported

Pierre Fabre and Maruho sign Japanese licensing agreement for pediatric beta-blocker

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...